NCT04311632: A trial that was reported late by ITB-Med LLC
This trial has reported, although it was 126 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04311632 |
|---|---|
| Title | A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin (rATG), as Induction Therapy in de Novo Renal Transplant Recipients |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 26, 2021 |
| Completion date | Oct. 3, 2023 |
| Required reporting date | Oct. 2, 2024, midnight |
| Actual reporting date | Feb. 6, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 126 |